ClinicalTrials.gov
public full text
Public Domain
A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
The primary study objective is to determine if microdoses of ABY-029 lead to detectable signals in sampled tissues with an EGFR pathology score ≥ 1 based on histological staining. The secondary study objective is to assess diagnostic accuracy of ABY-029 detection by iFI and intraoperative probe relative to histopathology diagnosis, and other indicators (e.g. proliferation, infiltration, etc.) as the gold standard, and to measure the molecular uptake and concentration of ABY-029 in resected specimens.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Correlation Between SPECT/CT and IDH Mutation in Brain Glioma#1127273
- Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC#1114528
- Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1#1009422
- Evaluation of [18F]-FMISO for Non Operated Glioblastoma#813165
- RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide#1114140
Record · ID 856429
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive